Broad studieson inhibition of the transporters, especially GAT1, resulted in thedevelopment of tiagabine (GAT1 inhibitor) which has been the onlyregistered drug targeting GABA transport so far.8−10 This anticonvulsantdrug is not devoid of substantial adverse reactions, such as asthenia,dizziness, nervousness, and depression.8 Therefore, the search for antiepileptic agents also includes otherGABA transporters as therapeutic targets. This evidence concerns the gene SLC6A1 and depressive symptom measurement.